title: Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.
abstract: Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain scarce.Methods. This is an observational prospective study including all patients that presented at our HIV Unit who interrupted TDF owing to nephrotoxicity. We assessed the evolution of renal parameters after discontinuation of this drug.Results. We included 59 patients, who were followed up for 72 weeks. Most were male (41, 69.5%), median (IQR) age was 53 (44; 58) years, and median time receiving TDF-containing regimens was 55.4 (28; 87.7) months. Most patients were receiving PI-based treatments (67%). At the final visit, most of the subjects showed complete recovery (35, 59.3%) or improvement (13 subjects, 22%). Significant improvements were observed in creatinine levels (from 84.9 [73.8; 97.5] to 78 [69.6; 91]μmol/L,p= 0.013), estimated glomerular filtration rate (eGFR, CKD EPI equation, from 87.7 [67; 99] to 89.9 [73.6; 99.3] mL/min/1.73 m2,p= 0.017), and number of patients with eGFR <60 mL/min/1.73 m2(from 9 [15.3%] to 1 [1.7%],p= 0.031). A trend toward significance was observed in abnormal urine proteinuria/creatinine ratio (from 22 [37%] to 8 [13.6%],p= 0.057).Conclusions. Our results corroborate the high frequency of complete or partial renal recovery in patients receiving TDF-containing regimens who discontinued therapy owing to nephrotoxicity.
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Anna
authors.identifier: 0000-0002-5343-2881
authors.initials: A
authors.lastname: Bonjoch
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Patricia
authors.identifier: 0000-0003-2755-3695
authors.initials: P
authors.lastname: Echeverría
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain; Statistics and Operations Research, Technical University of Catalunya, Barcelona, Spain.
authors.forename: Núria
authors.initials: N
authors.lastname: Perez-Alvarez
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Jordi
authors.identifier: 0000-0002-4075-0346
authors.initials: J
authors.lastname: Puig
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Carla
authors.initials: C
authors.lastname: Estany
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain; IrsiCaixa Foundation, Barcelona, Spain; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Barcelona, Spain.
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
authors.affiliation: Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Barcelona, Spain.
authors.forename: Eugènia
authors.identifier: 0000-0001-5298-1734
authors.initials: E
authors.lastname: Negredo
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D000068698:Tenofovir / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D000068698:Tenofovir